These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 33525802)

  • 21. Analysis of Gene Signatures of Tumor Microenvironment Yields Insight Into Mechanisms of Resistance to Immunotherapy.
    Wang B; Liu M; Ran Z; Li X; Li J; Ou Y
    Front Bioeng Biotechnol; 2020; 8():348. PubMed ID: 32528935
    [No Abstract]   [Full Text] [Related]  

  • 22. Biomimetic and Self-Assembled Nanoclusters Targeting β-Catenin for Potent Anticancer Therapy and Enhanced Immunotherapy.
    Liu J; Yan J; Yan S; Wang Y; Zhang R; Hou P; He W; Ji M
    Nano Lett; 2019 Dec; 19(12):8708-8715. PubMed ID: 31744296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T-cell exhaustion interrelates with immune cytolytic activity to shape the inflamed tumor microenvironment.
    Cai MC; Zhao X; Cao M; Ma P; Chen M; Wu J; Jia C; He C; Fu Y; Tan L; Xue X; Yu Z; Zhuang G
    J Pathol; 2020 Jun; 251(2):147-159. PubMed ID: 32222046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy.
    Boyero L; Sánchez-Gastaldo A; Alonso M; Noguera-Uclés JF; Molina-Pinelo S; Bernabé-Caro R
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33322522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment.
    Yang L; Li A; Lei Q; Zhang Y
    J Hematol Oncol; 2019 Nov; 12(1):125. PubMed ID: 31775797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.
    Spranger S; Sivan A; Corrales L; Gajewski TF
    Adv Immunol; 2016; 130():75-93. PubMed ID: 26923000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.
    Gajewski TF
    Semin Oncol; 2015 Aug; 42(4):663-71. PubMed ID: 26320069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
    Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
    J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas.
    Dodagatta-Marri E; Meyer DS; Reeves MQ; Paniagua R; To MD; Binnewies M; Broz ML; Mori H; Wu D; Adoumie M; Del Rosario R; Li O; Buchmann T; Liang B; Malato J; Arce Vargus F; Sheppard D; Hann BC; Mirza A; Quezada SA; Rosenblum MD; Krummel MF; Balmain A; Akhurst RJ
    J Immunother Cancer; 2019 Mar; 7(1):62. PubMed ID: 30832732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Wnt Signaling in Cancer Metabolism and Immunity.
    El-Sahli S; Xie Y; Wang L; Liu S
    Cancers (Basel); 2019 Jun; 11(7):. PubMed ID: 31261718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Altered cancer metabolism in mechanisms of immunotherapy resistance.
    Ramapriyan R; Caetano MS; Barsoumian HB; Mafra ACP; Zambalde EP; Menon H; Tsouko E; Welsh JW; Cortez MA
    Pharmacol Ther; 2019 Mar; 195():162-171. PubMed ID: 30439456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of Intrinsic Tumor Resistance to Immunotherapy.
    Rieth J; Subramanian S
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29724044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adaptive Resistance to Cancer Immunotherapy.
    McGray AJR; Bramson J
    Adv Exp Med Biol; 2017; 1036():213-227. PubMed ID: 29275474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance.
    Zheng W; Skowron KB; Namm JP; Burnette B; Fernandez C; Arina A; Liang H; Spiotto MT; Posner MC; Fu YX; Weichselbaum RR
    Oncotarget; 2016 Jul; 7(28):43039-43051. PubMed ID: 27343548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic Cell Vaccination in Metastatic Melanoma Turns "Non-T Cell Inflamed" Into "T-Cell Inflamed" Tumors.
    Bulgarelli J; Tazzari M; Granato AM; Ridolfi L; Maiocchi S; de Rosa F; Petrini M; Pancisi E; Gentili G; Vergani B; Piccinini F; Carbonaro A; Leone BE; Foschi G; Ancarani V; Framarini M; Guidoboni M
    Front Immunol; 2019; 10():2353. PubMed ID: 31649669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
    Chocarro de Erauso L; Zuazo M; Arasanz H; Bocanegra A; Hernandez C; Fernandez G; Garcia-Granda MJ; Blanco E; Vera R; Kochan G; Escors D
    Front Pharmacol; 2020; 11():441. PubMed ID: 32317979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.
    Tang H; Wang Y; Chlewicki LK; Zhang Y; Guo J; Liang W; Wang J; Wang X; Fu YX
    Cancer Cell; 2016 Mar; 29(3):285-296. PubMed ID: 26977880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.